A pilot study of treatment of lentigo maligna with 5% imiquimod cream

Fleming, Colin; Bryden, Alyson; Evans, Alan; Dawe, Robert S.; Ibbotson, S.H.

doi:10.1111/j.1365-2133.2004.05983.x

Cited by 95 publications

(79 citation statements)

References 8 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In man, topical treatment with imiquimod is used for enhancing immune response to treat external genital warts, diseases caused by papillomavirus, as well as basal cell carcinoma (25). It may also induce the regression of melanoma lesions (26,27). The mechanisms responsible for antitumor or antiviral effects of these immune modifiers are poorly understood but might involve the recruitment and activation of PDC.…”

Section: P Lasmacytoid Dendritic Cells (Pdc)mentioning

confidence: 99%

Virus or TLR Agonists Induce TRAIL-Mediated Cytotoxic Activity of Plasmacytoid Dendritic Cells

Chaperot

Blum

Manches

et al. 2006

The Journal of Immunology

229

266

View full text Add to dashboard Cite

Among dendritic cells, plasmacytoid dendritic cells (PDC) represent a functionally distinct lineage. Regarding innate immunity, PDC secrete large amounts of type I IFN upon viral exposure or stimulation by microbial products such as unmethylated CpG-motif containing oligo-DNA due to their selective expression of TLR7 and TLR9. We asked whether they could acquire cytotoxic functions during the early phases of infection or after activation with TLR7 or TLR9 agonists. In the present study, we describe a human PDC cell line called GEN2.2, derived from leukemic PDC, that shares most of the phenotypic and functional features of normal PDC. We show that after contact with the influenza virus, GEN2.2, as well as normal PDC, acquires TRAIL and killer activity against TRAIL-sensitive target cells. Moreover, we show that activation of GEN2.2 cells by CpG-motif containing oligo-DNA or R848 also induces TRAIL and endows them with the ability to kill melanoma cells. Therefore, PDC may represent a major component of innate immunity that could participate to the clearance of infected cells and tumor cells. This phenomenon could be relevant for the efficacy of TLR7 or TLR9 agonists in the therapy of infectious disease and cancer.

show abstract

Section: P Lasmacytoid Dendritic Cells (Pdc)mentioning

confidence: 99%

Virus or TLR Agonists Induce TRAIL-Mediated Cytotoxic Activity of Plasmacytoid Dendritic Cells

Chaperot

Blum

Manches

et al. 2006

The Journal of Immunology

229

266

View full text Add to dashboard Cite

show abstract

“…6 In 1 case an LM lesion almost cleared clinically but did not change histologically, 7 and in another case an LM lesion with a small hyperpigmented area recurred 9 months after the original clearance. 8 Owing to these possibilities, frequent clinical controls and a long follow-up are necessary.…”

Section: Inflammatorymentioning

confidence: 99%

Imiquimod Treatment of Lentigo Maligna: An Open-Label Study of 34 Primary Lesions in 32 Patients

Buettiker¹,

Yawalkar²,

Braathen³

et al. 2008

Arch Dermatol

View full text Add to dashboard Cite

L entigo maligna (LM) is an in situ lesion with a 2% to 50% risk of progression to LM melanoma. 1 Currently, surgery or radiotherapy is usually recommended as the primary treatment for LM. In the literature, the recurrence rates reported for radiotherapy range from 0% to 19%, with a mean recurrence rate of approximately 7%; in addition, radiotherapy carries the risk of causing chronic radiodermatitis or radiation-induced malignant neoplasm. 2 A margincontrolled excision using "slow Mohs" (rush permanent sections) and Mohs micrographic surgery has the lowest recurrence rate, perhaps as low as 3%. 3Methods. Thirty-two patients with 34 histologically confirmed facial LM lesions were enrolled in an open-label trial of imiquimod, 5%, cream (Aldara; 3M Pharma, Rueschlikon, Switzerland). No patient had been treated

show abstract

“…Topical treatment of melanocytic lesions resulted in clinical responses and depigmentation (Brown et al, 2005;Fleming et al, 2004).…”

Section: Melanocyte Lossmentioning

confidence: 99%

Hypopigmenting agents: an updated review on biological, chemical and clinical aspects

Solano¹,

Briganti²,

Picardo³

et al. 2006

Pigment Cell Research

620

524

View full text Add to dashboard Cite

SummaryAn overview of agents causing hypopigmentation in human skin is presented. The review is organized to put forward groups of biological and chemical agents. Their mechanisms of action cover (i) tyrosinase inhibition, maturation and enhancement of its degradation; (ii) Mitf inhibition; (iii) downregulation of MC1R activity; (iv) interference with melanosome maturation and transfer; (v) melanocyte loss, desquamation and chemical peeling. Tyrosinase inhibition is the most common approach to achieve skin hypopigmentation as this enzyme catalyses the rate-limiting step of pigmentation. Despite the large number of tyrosinase inhibitors in vitro, only a few are able to induce effects in clinical trials. The gap between in-vitro and in-vivo studies suggests that innovative strategies are needed for validating their efficacy and safety. Successful treatments need the combination of two or more agents acting on different mechanisms to achieve a synergistic effect. In addition to tyrosinase inhibition, other parameters related to cytotoxicity, solubility, cutaneous absorption, penetration and stability of the agents should be considered. The screening test system is also very important as keratinocytes play an active role in modulating melanogenesis within melanocytes. Mammalian skin or at least keratinocytes/melanocytes co-cultures should be preferred rather than pure melanocyte cultures or soluble tyrosinase.

show abstract

A pilot study of treatment of lentigo maligna with 5% imiquimod cream

Abstract: Topical imiquimod cream merits further investigation as a new therapy for LM.

Cited by 95 publications

References 8 publications

Virus or TLR Agonists Induce TRAIL-Mediated Cytotoxic Activity of Plasmacytoid Dendritic Cells

Virus or TLR Agonists Induce TRAIL-Mediated Cytotoxic Activity of Plasmacytoid Dendritic Cells

Imiquimod Treatment of Lentigo Maligna: An Open-Label Study of 34 Primary Lesions in 32 Patients

Hypopigmenting agents: an updated review on biological, chemical and clinical aspects

Contact Info

Product

Resources

About